News

In a real-world study of adults living with neuromyelitis optica spectrum disorder (NMOSD) in Japan, Uplizna (inebilizumab) was linked to fewer relapses, generally stable disability, and less use of corticosteroids. In addition, the approved therapy’s safety profile was consistent with what had been observed in earlier studies. “Our…

Treatment with Soliris (eculizumab) substantially reduces the risk and frequency of relapses in adults with neuromyelitis optica spectrum disorder (NMOSD) who test positive for antibodies against the aquaporin-4 (AQP4) protein. That’s according to a systematic review of published studies reporting results from clinical trials testing Soliris in this…

People with neuromyelitis optica spectrum disorder (NMOSD) report a greater burden of sleep problems and, when objectively monitored, spend more time in bed and sleeping than healthy people, according to a small study from Thailand. Data from 24 adults with NMOSD and self-reactive antibodies against the aquaporin-4 (AQP4) protein…

An international team of researchers identified a self-reactive antibody that may explain cases of neuromyelitis optica spectrum disorder (NMOSD)-like disease that test negative for known NMOSD-causing antibodies. Self-reactive antibodies against the protein modulator VRAC current 1 (MLC1) were identified in multiple people with NMOSD-like disease who lacked known disease-causing…

Treatment with Uplizna (inebilizumab-cdon) was associated with fewer attacks and reduced disability in Chinese adults with neuromyelitis optica spectrum disorder (NMOSD) who have anti-aquaporin-4 (AQP4) antibodies, a real-world study found. The estimated one-year attack-free rate was 95.5%. According to the researchers, the findings “provided evidence on the real-world…

MIL62, a treatment approved in China to treat neuromyelitis optica spectrum disorder (NMOSD), was superior to a placebo at preventing relapses and controlling disease activity in people with the autoimmune disease. That’s according to data from the Phase 3 portion of a China-based Phase 1b/3 clinical trial…

Immunosuppressive treatments can reduce the risk of disease relapses in people with neuromyelitis optica spectrum disorder (NMOSD) who test negative for known disease-driving antibodies, a review study showed. Because relapses in these patients often lead to permanent disability, the findings suggest that immunosuppressive treatment should be given early to…

Researchers have identified a mechanism by which the adult brain can replace astrocytes, the neuron-supporting cells in the brain that are attacked and lost in people with neuromyelitis optica spectrum disorder (NMOSD). Using mice with NMOSD-like disease, the researchers found that surviving astrocytes around lesions will replicate their DNA…

A global clinical trial testing Ultomiris (ravulizumab-cwvz) in adults with neuromyelitis optica spectrum disorder (NMOSD) found that the treatment kept patients free of relapses for more than 4.5 years. When compared with data from an external group of NMOSD patients given a placebo in a previous trial, the…

Children with neuromyelitis optica spectrum disorder (NMOSD) are more likely to have severe vision problems and incomplete visual recovery than those with the related condition myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). That’s according to a review of published studies involving children with NMOSD associated with antibodies against the aquaporin-4…